THE-NATURE-CONSERVANCY
22.4.2024 08:01:25 CEST | Business Wire | Press release
Today, the Government of Mongolia, The Nature Conservancy (TNC), and others announced the launch of Eternal Mongolia – a Project Finance for Permanence (PFP) initiative that will deliver lasting conservation and sustainable community development for the Central Asian country whose vast steppe represents our planet’s last great tract of intact temperate grassland.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240421544883/en/
Mongolia's Nationally Protected area, Toson Hulstai. ©TNC
Eternal Mongolia is a negotiated partnership that will deliver USD $198 million of new investment over 15 years to support Mongolia’s ambitious goals and deliver lasting conservation and sustainable community development in and around protected areas. This includes a USD $71 million transition fund from private and other global donor sources. This transition fund will accelerate Mongolia’s conservation and community development goals, while providing time to develop sustainable financing mechanisms to ensure protected areas can be managed sustainably in the long-term and that Mongolian people benefit from nature, now and for the future.
Eternal Mongolia will dramatically expand and strengthen the effectiveness of the country’s entire National Protected Area network, support sustainable herding practices, invest in the sustainable tourism industry, and set an unprecedented example to the rest of the world about the value of land and freshwater conservation.
The PFP will support local community-driven proposals to safeguard an additional 14.4 million hectares of Mongolia’s lands and waters including intact grasslands, forests, deserts, wetlands and rivers; strengthen the management of all of Mongolia’s National Protected Areas covering 47 million hectares; and extend sustainable and climate-resilient community-managed practices to 34 million hectares outside protected areas.
Mongolia established itself as a world conservation leader 30 years ago by committing to a vision revolutionary for its time: to protect 30% of its lands—a goal now shared around the world. Eternal Mongolia unlocks all the funding and policy commitments needed for Mongolia to ensure its 30% conservation target will be met by 2030 while providing a secure and economic future for Mongolians.
Eternal Mongolia is an initiative of Enduring Earth, an ambitious collaboration between The Nature Conservancy, The Pew Charitable Trusts, World Wildlife Fund (WWF) and ZOMALAB that works in partnership with nations and communities as they accelerate and amplify conservation for a more sustainable, prosperous future for people and planet.
“To address the dual climate and biodiversity crises we must catalyze action at scale and ensure that people and livelihoods are at the center of the solution,” said Jennifer Morris, CEO of The Nature Conservancy and Board Chair of Enduring Earth.
Eternal Mongolia anticipates key financial support from Legacy Landscapes Fund. Eternal Mongolia initiatives would not be possible without philanthropic support from Jennifer Speers, Pamela Tanner Boll, The Jeremy and Hannelore Grantham Environmental Trust, Joanna & Stuart Brown, The Lorinet Foundation, China Global Conservation Fund, Sabra Turnbull & Clifford Burnstein, Trafigura Foundation, Margaret A. Cargill Philanthropies, Arcadia, Fondation Hans Wilsdorf, The Gallogly Family Foundation, and Robert W. Wilson Charitable Trust.
The full version of this press release with more information and additional quotes, including those from the Government of Mongolia, can be found at www.nature.org/en-us/newsroom/eternal-mongolia-pfp-announcement/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240421544883/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
